Skip to content
DataLookout
Menu

NCT07166315

Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 3 words
    • Primary and study completion pushed from Mar 2027 to Jul 31, 2027
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of participants that have achieved Low Disease Activity (LDA) at 12 months.
Timeframe: At 12 months
Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months.
Timeframe: At 12 months
Change from baseline in PROM scores at 12 months.
Timeframe: At 12 months

Arms and interventions

Axial spondyloarthritis (axSpA)

Patients diagnosed with axial spondyloarthritis (axSpA) who are initiating treatment with bimekizumab, upadacitinib, or a tumour necrosis factor-alpha inhibitor.

Psoriatic arthritis (PsA)

Patients diagnosed with psoriatic arthritis (PsA) who are initiating treatment with bimekizumab, upadacitinib, risankizumab, guselkumab or a tumour necrosis factor-alpha inhibitor.

Other: observational study

Sites

1 site in 1 country

  • Royal National Hospital for Rheumatic DiseasesBath, Somerset, United Kingdom